Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth
January 19 2021 - 8:00AM
Business Wire
EmblemHealth coverage decision adds nearly 2.9 million covered
lives for Eversense CGM
Senseonics Holdings, Inc. (NYSE American: SENS) a medical
technology company focused on the development and commercialization
of long-term, implantable continuous glucose monitoring (CGM)
systems for people with diabetes, announced today that EmblemHealth
is now providing coverage for the Eversense® CGM System, effective
immediately. This recent coverage decision adds to the growing
number of payers who are writing Eversense into their CGM coverage
policies, as well as paying for the healthcare provider’s time for
the in-office sensor placement.
EmblemHealth of New York, New Jersey and Connecticut has added
coverage for Eversense in their 2021 CGM policy which expands
access to approximately 2.9 million residents of these three
states.
“We are excited to see additional coverage for Eversense and
appreciate the payer community’s recognition that CGM is now
Standard of Care for patients using insulin to manage their
diabetes,” said Tim Goodnow, PhD, President and Chief Executive
Officer of Senseonics. “Improved glucose control has always been
the goal for health care professionals and patients. Now that goal
is even more imperative as the COVID-19 pandemic has revealed the
negative consequences of poor glucose management in patients who
contract the coronavirus. Eversense offers patients a new choice
amongst the CGM class that delivers industry leading accuracy, an
improved patient experience, and an array of unique features
intended to afford people the opportunity to achieve improved
health outcomes.”
The Eversense CGM System consists of a fluorescence-based
sensor, a smart transmitter worn over the sensor to facilitate data
communication, and a mobile app for displaying glucose values,
trends and alerts. In addition to featuring the first long-term and
first implantable CGM sensor, the system is also first to feature a
smart transmitter that provides wearers with discreet on-body
vibratory alerts for high and low glucose and can be removed,
recharged and re-attached to the skin without discarding the
sensor. Eversense users now have the freedom to make treatment
decisions based on their Eversense readings. The sensor is inserted
subcutaneously in the upper arm by a health care provider via a
brief in-office procedure.
Patients who are interested in getting started on Eversense can
sign up at www.eversensediabetes.com/get-started-today. Physicians,
nurse practitioners or physician assistants interested in offering
the Eversense CGM System for their patients can contact 844-SENSE4U
(844-736-7348).
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration twice per day, and
when symptoms do not match CGM information or when taking
medications of the tetracycline class. The sensor insertion and
removal procedures are performed by a health care provider. The
Eversense CGM System is a prescription device; patients should talk
to their health care provider to learn more. For important safety
information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements about the
growth in payer coverage and nature of future coverage, and the
potential benefits Eversense offers people with diabetes, and other
statements containing the words “believe,” “expect,” “intend,”
“may,” “projects,” “will,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: uncertainties
in the development and regulatory approval processes, uncertainties
inherent in the commercial launch and commercial expansion of the
product, including without limitation coverage and other decisions
by payers, uncertainties relating to the benefits which may be
experienced by users, and such other factors as are set forth in
the risk factors detailed in Senseonics’ Annual Report on Form 10-K
for the year ended December 31, 2018, Senseonics’ Quarterly Report
on Form 10-Q for the quarter ended September 30, 2019, and
Senseonics’ other filings with the SEC under the heading “Risk
Factors.” In addition, the forward-looking statements included in
this press release represent Senseonics’ views as of the date
hereof. Senseonics anticipates that subsequent events and
developments will cause Senseonics’ views to change. However, while
Senseonics may elect to update these forward-looking statements at
some point in the future, Senseonics specifically disclaims any
obligation to do so except as required by law. These
forward-looking statements should not be relied upon as
representing Senseonics’ views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005300/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 investors@senseonics.com
Senseonics Media Contact: Mirasol Panlilio 301-556-1631
Mirasol.panlilio@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024